Myelodysplastic syndromes: More prevalent than we know

Geriatrics

Volumn 63, Issue 11, 2008, Pages 10-17

  Sandhu, Satinderpal K ^a   Sekeres, Mikkael A ^b  

^a METROHEALTH MEDICAL CENTER   (United States)

^b TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

Acute myelogenous leukemia; Elderly; Hematopoietic disorder; Macrocytic anemia; Myelodys plastic syndromes; Treatment

Indexed keywords

ARSENIC TRIOXIDE; DEFEROXAMINE; LENALIDOMIDE; RECOMBINANT ERYTHROPOIETIN; VALPROIC ACID;

ACUTE GRANULOCYTIC LEUKEMIA; ANEMIA; BLOOD TRANSFUSION; BONE MARROW BIOPSY; COMORBIDITY; DISEASE CLASSIFICATION; DISEASE COURSE; HUMAN; INCIDENCE; MYELODYSPLASTIC SYNDROME; REVIEW; AGE; AGED; ARTICLE; BIOPSY; BONE MARROW; PATHOLOGY; PREVALENCE;

AGE FACTORS; AGED; BIOPSY; BONE MARROW; DISEASE PROGRESSION; HUMANS; MYELODYSPLASTIC SYNDROMES; PREVALENCE;

EID: 58149147621     PISSN: 0016867X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (28)

1. Sekeres MA, List AF. Active treatment strategies improving outcomes in patients with myelodysplastic syndromes with the del(5q) abnormality. Clinical Leukemia. 2008:2(1): 28-33.
2. Sekeres MA, Fu AZ, Maciejewski JP. et al. A decision analysis to determine the appropriate treatment for low-risk myelodysplastic syndromes. Cancer. 2007;109(6):1125-1132.
3. Heaney ML, Golde DW. Myelodysplasia. N Engl J Med. 1999;340(21):1649 1660.
4. Howe RB, Porwit-Macdonald A, Wanat R, et al. The WHO classification of MDS does make a difference. Blood. 2004:103(9):3265-3270.
5. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 2007;89(6):2079-2088.
6. Myelodysplastic Syndrome. Medifocus Guidebook. February 2007. 〈http://www.medifocus.com〉
7. Steensma DP, Bennett JM. The myelodysplastic syndromes: diagnosis and treatment. Mayo Clin Proc. 2006;81(1):104-130.
8. Sekeres MA, Kantarjian H. List A, et al. Characteristics of patients with myelodysplastic syndromes (MDS) in the United States from 4528 physician surveys (Poster). Blood. 2007;2462:726a.
9. Ma X, Does M, Raza A, et al. Myelodysplastic syndromes: incidence and survival in the United States. Cancer. 2007;109(8):1536-1542.
10. Shadduck RK, Latsko JM, Rossetti JM, et al. Recent advances in myelodysplastic syndromes. Exp Hematol. 2007:35(4 Suppl 1):137-143.
11. Guralnik JM, Eisenstaedt RS, Ferrucci L, et al. Prevalence of anemia in persons 65 years and older in the United States: evidence for a high rate of unexplained anemia. Blood. 2004;104(8):2263-2268.
12. Deschler B, de Witte I, Mertelsmann R, Lübbert M. Treatment decision-making for older patients with high-risk myelodysplastic syndrome or acute myeloid leukemia: problems and approaches. Haematotogica. 2006:91(11):1513-1522.
13. Tilly-Gentric A, Malo JP, Marion V. Primary myelodysplasia: management and outcome at 3 years in 45 patients age 65 and older, J Am Geriatr Soc. 2001:49(10):1358-1360.
14. Friedberg JW, Neuberg D, Stone RM, et al. Outcome in patients with myelodysplastic syndrome after autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol. 1999;17(10):3128-3135.
15. Cassola M, Malcovati L. Myelodysplastic syndromes-coping with ineffective hemato-poiesis. N Engl J Med. 2005:352(6):536-538.
16. Steenmsa DP, List AF. Genetic testing in myelodysplastic syndromes: molecular insights into hematologic diversity. Mayo Clinic Proc. 2005;80(5):681-698.
17. Wimazal F. Sperr WR, Kundi M. et al. Prognostic significance of serial determinations of lactate dehydrogenase (LDH) in the follow-up of patients with myelodysplastic syndromes. Ann Oncol. 2008;19(5):970-976.
18. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 1982;51{2):189-199.
19. Malcovati L, Delia Porta MG, Pascutto C, et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol. 2005;23(30):7594-7603.
20. Malcovati L, Germing U, Kuendgen A, et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol. 2007;25(23):3503-3510.
21. Yichayaou B, Cohen AM, Grosman B, et al. Prevalence and survival of myelodsyplastic syndrome of the refractory anemia type in hospitalized cognitively different geriatric patients. Gerontology. 2000;46(6): 323-327.
22. Park S, Grabar S, Kelaidi G, et al. Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience. Blood. 2008;111(2):574-582.
23. Garcia-Manero G, Yang AS, Jagasia M. Evaluating new treatment options for MDS. Clin Adv Hematol Oncol. 2007;5(11):l-9.
24. List A, Kurtin S, Roe DJ, et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med. 2005;352(6):549-557.
25. Golshayan AR, Jin T, Maciejewski J, et al. Efficacy of growth factors compared to other therapies for low-risk myelodysplastic syndromes. Br J Haematol. 2007:137(2):125-132.
26. Steensma DP, Tefferi A. Risk-based management of myelodysplastic syndrome. Oncology. 2007;21(l):43-54.
27. Fenaux P, Mufti GJ, Santini V, et al. Azacitidine (AZA) treatment prolongs overall survival (OS) in higher-risk MDS patients compared with conventional care regimens (CCR): results of the AZA-001 phase III study. Blood. 2007;110:Abstract 817.
28. Sekeres MA. Arsenic trioxide as a treatment for myelodysplastic syndrome. Curr Hematol Rep. 2005;4(1):59-63.